Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that a Saniona molecule, previously known as AN-470 and now referred to as BI-1030, will be made accessible for open scientific research through Boehringer Ingelheim’s Open Innovation platform, opnMe.com. This molecule was synthesized as part of Saniona’s proprietary GABAA a5 Negative Allosteric Modulator (NAM) program, which was further developed in collaboration with Boehringer Ingelheim from 2016-2020.

Janus S. Larsen, CDO of Saniona, commented, “We have demonstrated that BI-1030 is a highly potent and selective negative modulator of GABAA a5 channels. Given its exceptionally clean and selective profile, this molecule could serve as a valuable reference test compound and potentially become a gold standard for academic scientific research in this field. We appreciate that Boehringer Ingelheim has proposed and agreed with us to make this molecule freely available to the scientific community via their platform”.

Saniona holds exclusive global rights to the GABAA a5 NAM program following the termination of the collaboration with Boehringer Ingelheim in November 2020. Additionally, Saniona recently selected another compound, SAN2465, from the GABAA a5 program for pre-clinical development as a rapid-acting antidepressant.

For further information on Boehringer Ingelheim’s Open Innovation platform, please visit opnMe.com.

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona’s most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, please visit www.saniona.com.

Attachments
Saniona and Boehringer Ingelheim (BI) make molecules from previous collaboration available for BI´s Open Innovation platform

© Modular Finance, source Nordic Press Releases